Bausch + Lomb Corp

Bausch + Lomb delivered a solid third quarter, posting adjusted EPS of $0.18 against a consensus estimate of $0.16, a 12.50% beat, as broad-based revenue growth and improving operational efficiency carried the eye-health company ahead of expectations. Revenue rose 7.1% year-over-year to $1.28 billion, with all three segments contributing, led by Vision Care at $736.00 million and Pharmaceuticals at $330.00 million, the latter buoyed by strong uptake of MIEBO in the dry eye market. Operating income more than doubled to $95.00 million from $43.00 million a year ago, reflecting higher sales volumes and tighter expense management, though a swing in the tax provision pushed the GAAP result to a net loss of $28.00 million. Adjusted EBITDA climbed to $243.00 million from $212.00 million. Shares rose in pre-market trading on the profitability beat, and management reinforced confidence by narrowing full-year 2025 Adjusted EBITDA guidance to $870.00 million-$910.00 million while maintaining revenue guidance of $5.05 billion-$5.15 billion.